Your session is about to expire
← Back to Search
Amino Acid Derivative
L-Carnosine for Schizophrenia (CACTIS Trial)
Phase 2 & 3
Waitlist Available
Led By Avi Reichenberg, PhD
Research Sponsored by Abraham Reichenberg
Eligibility Criteria Checklist
Specific guidelines that determine who can or cannot participate in a clinical trial Must have
Treatment with stable doses of antipsychotic medications for at least 4 weeks prior to the screening visit.
Age 18-60, males and females.
Timeline
Screening 3 weeks
Treatment Varies
Follow Up 8 weeks and 10 weeks
Awards & highlights
CACTIS Trial Summary
This study is evaluating whether a drug may help improve cognition for individuals with schizophrenia.
CACTIS Trial Eligibility Criteria
Inclusion Criteria
You may be eligible if you check “Yes” for the criteria belowCACTIS Trial Timeline
Screening ~ 3 weeks3 visits
Treatment ~ Varies
Follow Up ~ 8 weeks and 10 weeks
Screening ~ 3 weeks
Treatment ~ Varies
Follow Up ~8 weeks and 10 weeks
Treatment Details
Study Objectives
Outcome measures can provide a clearer picture of what you can expect from a treatment.Primary outcome measures
Cognitive Training Score
Secondary outcome measures
Change in Performance Advantage
Matrix Consensus Cognitive Battery (MCCB)
The Learning Rate
CACTIS Trial Design
2Treatment groups
Experimental Treatment
Placebo Group
Group I: L-CarnosineExperimental Treatment2 Interventions
oral doses of 2000mg for 4 weeks total - 2 weeks medication phase only, and then 2 weeks combined treatment with cognitive training.
Group II: PlaceboPlacebo Group2 Interventions
matching placebo
Treatment
First Studied
Drug Approval Stage
How many patients have taken this drug
Cognitive Training
2008
Completed Phase 3
~4100
L-Carnosine
2015
Completed Phase 3
~60
Find a Location
Who is running the clinical trial?
Abraham ReichenbergLead Sponsor
Stanley Medical Research InstituteOTHER
140 Previous Clinical Trials
10,336 Total Patients Enrolled
83 Trials studying Schizophrenia
6,286 Patients Enrolled for Schizophrenia
Avi Reichenberg, PhDPrincipal InvestigatorIcahn School of Medicine at Mount Sinai
Frequently Asked Questions
These questions and answers are submitted by anonymous patients, and have not been verified by our internal team.
Share this study with friends
Copy Link
Messenger